Impact assessment of vaccine-related negative news and incentive measures on vaccine hesitancy in Hong Kong

Yifan Chen[1], Yang Ye[2], Hsiang-Yu Yuan[3,4], Qingpeng Zhang[5,6*]

[1]School of Data Science, City University of Hong Kong, Hong Kong, China.

[2]Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, Yale University, New Haven, CT, USA.

[3]Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.

[4]Centre for Applied One Health Research and Policy Advice, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.

[5]Musketeers Foundation Institute of Data Science, The University of Hong Kong, Hong Kong, China.

[6]Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

*qpzhang@hku.hk (https://orcid.org/0000-0002-6819-0686)

Abstract

Vaccine hesitancy underscores the critical need to quantify how diverse factors shape vaccine uptake. We develop a social-epidemiological transmission model with a game-theoretic imitation mechanism and payoff-driven risk perception to assess the impacts of vaccine-related negative news and incentive measures on COVID-19 vaccine uptake during the pandemic. By fitting our model with real-world data from Hong Kong, we reveal that the negative news drastically

impeded vaccination efforts. Scenario analyses suggest that, without incentive measures, the

projected fifth wave of COVID-19 in Hong Kong (from December 31, 2021, to October 15,

2022) would have infected 97.3% of the population, resulting in an estimated 48,892 deaths.

Both model simulation and real-world data demonstrate that incentive measures have

successfully encouraged vaccine uptake and saved approximately 39,073 lives. However, we

found that vaccine willingness declined rapidly after the incentive measures discontinued,

implying limited benefits in mitigating the effect of negative news in the long run. This study

also highlights the need for booster doses in the face of the immune escape of the Omicron

variants. Our model offers data-driven insights into the interplay between negative news, vaccine

hesitancy, and incentive measures, shedding light on the effective preparation for emerging

infectious disease outbreaks.

Introduction

Vaccine hesitancy has been among the top ten global health threats identified by the World

Health Organization (WHO)[1]. The ongoing mutations of COVID-19 highlight the need to

address vaccine hesitancy, as it can lead to repeated infections and elevate the risk of developing

Long COVID[2,3]. Vaccine hesitancy extends beyond COVID-19. Recent WHO statistics indicate

that vaccination coverage rates for measles, diphtheria-tetanus-pertussis (DTP), and human

papillomavirus (HPV) fall short of established targets[4]. This reluctance to vaccinate undermines

the United Nations' Sustainable Development Goal (SDG) of healthy lives and well-being for all

at all ages[5]. Addressing vaccine hesitancy is essential for achieving better health outcomes

globally.

Vaccine hesitancy is multifactorial, spanning psychological, social, and structural

dimensions[6], which can be conceptualized through the 5C scale[7]: *confidence*[8–12] (trust in vaccine

safety and efficacy, delivery systems, and governance), *complacency*[13–15] (perceived low risk of

disease or lack of urgency to vaccinate), *constraints*[16] (barriers such as cost, access, or logistical

limitations), *calculation*[17–19] (active information seeking), and *collective responsibility*[20,21] (the

willingness to protect others by one's own vaccination by means of herd immunity).

Notably, negative news directly erodes confidence (e.g., safety scandals[10,11,22]) and fuels

calculation (e.g., misinformation-driven risk overanalysis[23]). Historical misuse of medical and

vaccine research during the colonial era in Africa continues to affect COVID-19 vaccination

rates on the continent[24]. Negative news has stronger effects on public trust than positive news,

often resulting in greater public engagement[25–27] and the proliferation of conspiracy theories and

misinformation[28]. Negative news thrives in polarized environments: right-wing or conservatives

exhibit relatively higher susceptibility to conspiracy theories and misinformation[18,29–35], often

exacerbating vaccine hesitancy under the governance of right-wing parties or the claim of

prominent anti-vaccine activists. Conversely, incentive measures primarily address constraints

but may indirectly affect confidence through institutional trust signaling.   In Europe, cash

incentives were effective in boosting vaccination rates[36]. Interestingly, smaller cash rewards

positively affected vaccination rates more than higher cash rewards[37]. However, several studies

have shown that negative news regarding the Oxford AstraZeneca vaccine did not affect its

uptake in the UK and Denmark[38–40], and economic incentives did not increase overall

vaccination rates at all in the United States[41,42]. Additionally, a previous study has indicated that

in Hong Kong, the incentive measures have little impact on encouraging older adults to get

vaccinated[43].

The COVID-19 epidemic in Hong Kong provides an ideal case study, offering a real-life

experimental setting to assess the impact of vaccine-related events on vaccine hesitancy. During

the pandemic, the public willingness to get vaccinated declined due to vaccine-related negative

news, including packaging defects, serious adverse events after vaccination, and reduced

information about deaths possibly linked to vaccination[44–46]. Subsequently, various incentive

measures were introduced, including material gifts, economic rewards, and vaccination leave[47].

While many surveys have examined the effects of various factors on vaccine hesitancy in Hong

Kong[48–52], predefined surveys often fail to capture all relevant factors and events, and limited

sample sizes often lead to selection bias. Thus, understanding these vaccine-related events is

crucial for addressing vaccine hesitancy effectively.

In this study, we aim to leverage real epidemiological data to assess the impact of vaccine-

related negative news and incentive measures on vaccine hesitancy in Hong Kong. We develop a

social-epidemiological model to account for key events affecting vaccine uptake. With this

model, we conduct scenario analyses to evaluate how these elements affect the number of

infections and deaths.

Results

To evaluate the impact of vaccine-related events on vaccine uptake in Hong Kong, we used a

deterministic, SEIRD-like model-based framework to model COVID-19 epidemic dynamics and

daily vaccination administration (see Supplementary Fig. 1). This model incorporated time-

varying daily vaccination rates modulated by risk perception dynamic, where vaccine uptake is

quantified through a composite payoff function comprising three synergistic components:

infection risk and mortality risk reduction after vaccination, and vaccine-related events including

negative news and incentive measures.

Model-based infection-vaccination dynamics and event-driven behavioral shifts

We explored the impact of vaccine-related negative news and incentive measures on infection-vaccination dynamics in Hong Kong. To do so, we first fitted the social-epidemiological model to daily reported infected cases and count of vaccination in Hong Kong. The study period spanned from January 24, 2020, to October 15, 2022, which was delineated into three phases based on vaccine availability (see the Methods for more details). Our model successfully reproduced the epidemic dynamics and daily vaccination trends across the study period, with reasonable consistency between observed data and model fits (see Fig. 1 for fits; Supplementary Figs. 2-12 for full model diagnostics). Of note, fits were poorer for the booster vaccination phase due to the limitations of segmented modeling (Fig. 1c). These segments were driven by two key events: E1 (February 26, 2022): a sudden surge in reported infected cases because the government included positive RAT (rapid antigen tests) cases in official statistics; E2 (May 23, 2022): the emergence of a new epidemic wave. Nonetheless, the consistency of fits across multiply-independently sampled chains allowed us to reliably assess the impact of vaccine-related events on vaccine uptake in Hong Kong.

We used the estimated payoff gains to quantify how screened critical events influenced people's willingness to get vaccinated (Table 1). The analysis revealed that negative news substantially reduced the perceived benefits of vaccination. Notably, the vaccine packaging defects (E0) led to a reduction in the payoff gain, decreasing it by 232.4% (95% CI: 158.3%-306.5%). This event had a markedly greater impact on vaccination hesitancy compared to the other two events, the serious adverse events after vaccination (T1: 100.7%, 95% CI: 76.6%-124.9%) and reduced information about deaths possibly linked to vaccination (T3: 77.1%, 95% CI: 40.0%-114.2%).

Figure 1. COVID-19 epidemic dynamics and vaccination in Hong Kong (Jan. 2020-Oct. 2022).

(a) Daily new reported infected cases (blue circles) and model-fitted transmission trend (red line;

95% CI shaded); (b)-(c) Daily count of vaccination (magenta diamonds) and model-fitted

vaccination rates; (d) Zoomed-in view of the marked period in panel a (dashed shaded grey box)

showing detailed fitting. Black dotted line in panel b and c show timepoints of fitting

segmentation (E0-E2). Gray dashed lines in panel b show timepoints of four critical events (T1-

T4).

120   In response to a slow vaccine rollout of COVID-19, the Hong Kong government and local

121   private sectors introduced several incentive measures (T2) to encourage vaccination, including

122   lucky draws and cash bounties, which increased the benefits of receiving primary vaccine doses.

123   However, their effect was temporary, as evidenced by a reduction in payoff gain once these

124   reward programs concluded (T4: 94.6%, 95% CI: 66.1%-123.1%).

125   **Table 1.** The impact of different events on vaccine uptake.

Timepoints of events	Events	Potential 5C scale	Payoff gains for primary vaccination series
2021.03.24	E0: Vaccine packaging defects	Confidence	-130.8(-232.4%)
2021.04.19	T1: Serious adverse events after vaccination	Confidence	-71.9(-100.7%)
2021.05.26	T2: Government and business incentive measures	Constraints, confidence	64.6(90.6%)
2021.06.01	T3: Reduced information about deaths possibly linked to vaccination	Confidence, calculation	-55.0(-77.1%)
2021.08.08	T4: End of the incentive measures	Constraints	-67.5(-94.6%)

Impact of negative news mitigation on vaccination uptake and epidemic trajectories

Our simulations demonstrated how mitigating the effects of negative news can alter vaccination

trends and ultimately reduce the public health burden of COVID-19. We simulated the

transmission dynamic and daily vaccination rates under four scenarios without incentive

measures (Fig. 2): (1) negative news only (the scenario with negative news but without incentive

measures; the yellow curve); (2) no news & incentives (the scenario with neither negative news

nor incentive measures; the teal curve); (3)-(4) mitigating 50% and 25% of the effects of

negative news without incentive measures, respectively (purple and dark brown curves). These

simulations were compared to the actual scenario (red curve) to assess how different levels of

negative news influence vaccination rates and transmission dynamics.

Figure 2. COVID-19 epidemic dynamics and vaccination over time under scenarios without

incentive measures (primary vaccination series phase). (a) The transmission trend; (b)

Vaccination rates. The solid curves and bands represent the mean of fitted or simulated results,

and 95% confidence intervals, respectively. The simulated results of scenarios are represented in

yellow, teal, purple and dark brown, respectively.

Comparing the "negative news only" scenario with the actual scenario, we found that,

without any incentive measures, the daily vaccine uptake could be much lower than that of the

actual scenario. Upon the arrival of the Omicron variant, the epidemic would peak earlier than

anticipated, with peak daily infections reaching 3.81 times (95% CI: 1.11-6.50) the actual peak.

Without the negative news, daily vaccinations would continue to rise until reaching maximum

capacity and remain steady until mid-August, achieving the first primary doses vaccination rate

of 99.7% by booster dose rollout—56.5% higher than actual figures.

With universal primary vaccination doses, the Omicron wave in mid-January 2022 would

be averted, substantially reducing infection and mortality rates. However, by late July 2022, a

more serious wave of outbreaks would emerge caused by the Omicron mutant strain sub-lineages

BA.4/BA.5[53]. In this scenario, the projected cumulative number of infections was approximately

4.02 million, which was 2.19 million more than the fitted actual figure. Despite the increase in

infected cases, an estimated 5,284 lives would be saved by the study's conclusion.

Additionally, we found that without incentive measures, the government must mitigate at

least 50% of the negative news impact to achieve high coverage (99.7%) of the population

receiving primary doses by booster dose rollout. As a result, the fifth wave of outbreak in Hong

Kong (in early 2022) could have been prevented.

The synergistic effect of introducing incentive measures and mitigating negative news

Our simulations demonstrated that combining partial mitigation of negative news with incentive

measures substantially enhanced vaccination coverage, but booster dose incentives were critical

to countering Omicron immune evasion. We examined how the proper mitigation of negative

news may affect the daily infection and vaccination rates under three scenarios with incentive

measures (Fig. 3): (1) incentive measures only (the scenario without negative news but with

incentive measures; the yellow curve); (2)-(3) mitigating 10% and 5% of the impact of negative

news with incentive measures, respectively (since incentive measures can compensate for

approximately 50.9% of the impact of negative news, shown in Table 1).

In both the scenarios "no news & incentives" and "incentive measures only", the daily

vaccine uptake shared a similar pattern regardless of the incentive measures (as shown by the

yellow and teal curves in Fig. 3). Importantly, introducing incentive measures could effectively

reduce vaccine hesitancy so that as little as 5% negative news mitigation was sufficient to

prevent the fifth outbreak. However, merely increasing the vaccination rate of the two primary

doses was insufficient to prevent the future outbreak due to the immune escape of the Omicron

variants and the low booster dose vaccine uptake (Fig. 3a, Aug. 2022).

Figure 3. COVID-19 epidemic dynamics and vaccination over time (primary vaccination series

phase). (a)-(b) The transmission trend and vaccination rates under four scenarios. The solid

curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals,

respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark

brown, respectively.

To address this challenge, we simulated how the incentive measures for booster doses to

contain the future outbreak. The results showed that if small- to medium-level (25% to 50%)

incentive measures were introduced for booster doses after the primary doses vaccination

program, the future Omicron-led outbreak could be curbed, potentially reducing infections by 6.4

million and saving 4,748 lives throughout the study period, compared with a scenario without

any incentive measures for booster doses (Fig. 4).

Figure 4. COVID-19 epidemic dynamics over time (booster vaccination phase). The

transmission trend under three scenarios. The solid curves and bands represent the mean of fitted

or simulated results, and 95% confidence intervals, respectively. The simulated results of

scenarios are represented in teal, dark brown and light blue, respectively.

Discussion

In our study, we fit real epidemic dynamic data to understand how vaccine-related events

influenced vaccine uptake in Hong Kong. Our research offers evidence and insights, highlighting

the positive synergistic effect of managing negative news and introducing incentive measures to

achieve herd immunity. We recommend that only modest incentive measures for booster doses

are sufficient to control outbreaks caused by immune escape.

This study provides data-driven evidence for previous survey studies[49–51,54], assessing the

importance of specific vaccine-related events, including the impact of negative news and

incentive measures on vaccine uptake. Negative news may reduce vaccination willingness

through dual pathways: *confidence* (reports of adverse events and packaging defects reduced

trust in vaccine safety, which is a primary concern across all age groups in Hong Kong[49]) and

calculation (reduced information about deaths prolonged risk-benefit analysis). Negative news

may directly undermine trust in the government and contribute to the spread of misinformation

and rumors, which has been shown further to amplify vaccine hesitancy through compounded

psychological and social mechanisms[55]. Mitigating the effects of negative news by 50% can

achieve high coverage of the first two primary doses and save costs on incentive measures,

allowing resources to be reallocated toward increasing vaccine supply, expanding healthcare

capacity, and supporting economic growth. Notably, previous research has shown that providing

information about vaccine risks does not influence willingness to vaccinate[56,57]. Our results

suggest that the timely, proper, and transparent publicity of pandemic and vaccine safety-related

information could boost vaccination rates by mitigating misinformation originating from

negative news. Our findings show that incentive measures may compensate 50.9% of negative

news's impact through *constraints* to boost vaccine uptake. Ultimately, it will aid in the faster

achievement of herd immunity and minimize unnecessary infections and deaths. However, their

effects are short-term, and vaccine hesitancy remains slightly increased after the incentive

measures end.

Our results shed light on the fact that even with high vaccine coverage of first primary

doses, neglecting booster doses could lead to a stronger outbreak of Omicron in Hong Kong. The

principle underlying the outbreak is the accumulation of susceptible individuals and the

relaxation of PHSMs, which aligns with our previous research on respiratory infectious

diseases[58,59]. In addition, the Omicron BA.4/BA.5 resurgence despite high primary dosing further

highlights *complacency*'s role in the low infection phase, which implicated waning variant

vigilance. Thus, when addressing future virus spread and vaccine promotion, the government

should not only focus on current epidemic dynamics but also consider virus characteristics to

develop seamless and comprehensive strategies. Fortunately, we observed that minimal incentive

measures for booster doses can prevent this outbreak. The synergistic effect of combining

incentive measures and negative news mitigation indicates a cost-effective approach to

promoting vaccination programs during an epidemic.

Our research has limitations. First, our study's timeframe was limited to data available up to

October 15, 2022, due to the availability of Google Mobility data. It is important to identify

alternative public human mobility data for future epidemic surveillance and modeling. Second,

this study did not explore how negative news and incentive measures affect different

socioeconomic groups. A study has indicated that in Hong Kong, incentive measures have little

impact on encouraging older adults to get vaccinated[43]. Our model is flexible and can be easily

extended to account for the composition of different subpopulations, aiding the formulation of

more targeted policy measures. It is important to explore age-specific responses to these key

events given representative survey data. Third, our study focused on data from Hong Kong. To

expand our research to other regions, we would require relevant epidemic data and event

information from each area. However, some regions lack available data, which limits our study

to Hong Kong. Nonetheless, our model can be easily adjusted to evaluate vaccine-related events

in different regions, helping them develop vaccination strategies suited to their specific needs.

In summary, our research assessed the effects of negative news and incentive measures on

vaccine willingness during the COVID-19 crisis. We highlighted the importance of mitigating

the impact of negative news and the positive effect of incentive measures on increasing vaccine

uptake. Our model can be adapted to various national and regional contexts, making it a valuable

tool for evaluating certain events. It also offers scalability to address future outbreaks, providing

the government with valuable insights to effectively promote vaccines in response to different

viral threats.

Methods

Data Source

We obtained daily reported COVID-19 infected cases (January 24, 2020, to October 15, 2022)

and vaccination doses (February 26, 2021, to October 15, 2022) from the DATA.GOV.HK

database[60]. According to the availability of vaccines, we divided the Hong Kong epidemic into

three phases based on the vaccination plan: (1) pre-vaccination phase; from January 24, 2020, to

February 25, 2021, during which the Hong Kong government relied solely on PHSMs to control

the epidemic; (2) primary vaccination series phase; from February 26, 2021, to November 10,

2021, during which citizens could begin receiving the first two primary doses of Sinovac and

BioNTech vaccines in addition to PHSMs; (3)booster vaccination phase; from November 11,

2021, to October 15, 2022, during which citizens could start receiving booster doses of the

vaccine. We exclusively focused on locally acquired infections to isolate local transmission

dynamics under Hong Kong's stringent border quarantine policies. Five case categories -

epidemiologically linked with local case, epidemiologically linked with possibly local case, local

case, locally acquired case, and possibly local case – were consolidated into a unified *local*

transmission category. A 7-day moving average was applied to mitigate reporting delays and

weekday fluctuations in case counts. We aggregated Sinovac (CoronaVac) and BioNTech

(Comirnaty) recipients for vaccination data, assuming comparable vaccine efficacy between the

two vaccines. The contact matrix in Hong Kong was projected using empirical data from the

COVID-19 era[61]. Additionally, daily mobility trends during the study period were extracted from

Google community mobility reports[56]. We used the average changes in *retail and recreation*

percent change from baseline and *transit stations percent change from baseline* to represent the

extent of mobility changes in Hong Kong under different PHSMs implementations during the

epidemic.

Model Structure

We proposed a social-epidemiological transmission model based on the SEVPIRD-CT

framework (susceptible, exposed, vaccinated, presymptomatic, infected, recovered, deceased,

contact-traced), as illustrated in Supplementary, Fig. 1. Susceptible individuals enter an exposed

(E) state upon infection, characterized by a latent period with no infectiousness. Following

latency, they transition to a presymptomatic (P) state, becoming infectious but remaining

asymptomatic. Presymptomatic individuals are either identified via contact tracing (CT) and

isolated upon symptom onset or progress to the infected (I) state, with eventual transition to

recovered (R) or deceased (D) compartments.

During the phase of vaccination programs, susceptible individuals move to a vaccinated (V)

state upon immunization. Breakthrough infections in vaccinated individuals follow the same

progression $(E \rightarrow P \rightarrow I \rightarrow R/D)$ but with reduced mortality rates calibrated to vaccine

efficacy. We incorporated imitation dynamics reflecting social learning processes to capture

temporal shifts in vaccine uptake behavior. The daily vaccination willingness (y^H) evolves

according to:

$$\frac{dy^H}{dt} = \kappa^H y^H (1 - y^H) \left[(\beta^{H_0} - \beta^H) + r_{CFR}^H (CFR^{H_0} - CFR^H) + \Psi_{baseline} + \sum \Psi_{Events} \right]$$

where y represents the proportion of individuals vaccinated daily based on the daily maximum

appointment vaccination capacity. H_0 and H act paired vaccination status (e.g., $H_0 = $

unvaccinated, $H = $ fully vaccinated; $H_0 = $ fully vaccinated, $H = $ received a booster dose). κ

denotes the imitation rate at which individuals sample others and switch vaccinating behavior,

while β and CFR stand for the transmission rate and case fatality rate of administering the dose

H_0 or H. r is the adjustment coefficient for the difference in case fatality rates. Ψ_{Events}

signifies the payoff gain following different vaccine-related events. The aggregated value of

terms within the square brackets quantifies population-level risk perception, whereby the

algebraic sign (positive/negative) governs the behavioral inclination toward vaccination—

positive values amplify vaccine uptake through perceived benefit dominance, while negative

values suppress it via risk aversion dominance.

Statistical Analysis

We fitted the daily reported cases for each wave of the epidemic in Hong Kong, as well as the

daily number of vaccinations during the vaccination program implementation period, using

MCMC methods with the MCMCstat toolbox[64]. The model parameter values for each epidemic

wave are presented in Supplementary Table 1. We randomly generated 10,000 sets of parameters

using Latin Hypercube Sampling (LHS). After running all parameter sets, we selected the three

sets with the most minor errors as our initial parameter sets.

For fitting each phase, we further divided each phase into segments based on the number of

epidemic waves and the occurrence of certain events. For the first segment fitting, we assumed

that an individual in the presymptomatic stage entered a population entirely susceptible to

infection. The initial values for fitting each subsequent segment were set as the ending values of

the previous segment. We used the Poisson likelihood function as the loss function for daily

reported cases and vaccination numbers.

Finally, we estimated the convergence of the MCMC chains using the Gelman-Rubin

diagnostic. Once the MCMC chains converged and stabilized, we randomly selected 500

parameter sets from the burn-in phase (half the chain length) to generate 95% confidence

intervals based on these 500 parameter sets.

Events Screening

A previous study surveyed Hong Kong to determine reasons for vaccine hesitancy across

different age groups[49]. After excluding personal factors like concerns about chronic diseases,

already antibodies, and lack of social norms or support, the top three reasons were identified for

each group. These reasons were then grouped into vaccine-specific issues, low trust in the

government, and a lack of urgency or perceived need for vaccination. To select relevant events,

we applied polynomial fitting to daily vaccination data to find inflection points in the rate

changes. These were identified on April 19, May 13, June 30, July 15, August 5, October 27, and

November 7, 2021. Considering the lead or lag time of events[65], related news was reviewed from

the Department of Health press releases[66] and the Oriental Daily News[67] within 28 days before

and after these dates. The events listed in Table 1 were then chosen, and their impact on vaccine

hesitancy in Hong Kong was measured.

Data availability

Data of COVID-19 reported cases, death numbers and count of vaccination were retrieved from

official source (https://data.gov.hk/en-data/dataset/hk-dh-chpsebcddr-novel-infectious-agent

(2023) and https://data.gov.hk/en-data/dataset/hk-hhb-hhbcovid19-vaccination-rates-over-time-

by-age (2023)). Mobility changes were retrieved from

(https://www.google.com/covid19/mobility/)

Code availability

337   The fitting and analysis codes are publicly available at https://github.com/yifan7-

338   chen/Vaccine_Hesitancy

References

1. World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-

room/spotlight/ten-threats-to-global-health-in-2019.

2. COVID-19 Real-Time Learning Network. COVID-19 Variant Update.

https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-

update/#/+/0/publishedDate_na_dt/desc/.

3. Centers for Disease Control and Prevention. Long COVID. https://www.cdc.gov/covid/long-

term-effects/index.html.

4. United Nations International Children's Emergency Fund. Immunization.

https://data.unicef.org/topic/child-health/immunization/ (2024).

5. United Nations. The 17 Sustainable Development Goals. https://sdgs.un.org/goals.

6. MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**, 4161–

4164 (2015).

7. Betsch, C. *et al.* Beyond confidence: Development of a measure assessing the 5C

psychological antecedents of vaccination. *PLOS ONE* **13**, e0208601 (2018).

8. Soares, P. *et al.* Factors Associated with COVID-19 Vaccine Hesitancy. *Vaccines* **9**, 300

(2021).

9. Prickett, K. C., Habibi, H. & Carr, P. A. COVID-19 Vaccine Hesitancy and Acceptance in a

Cohort of Diverse New Zealanders. *Lancet Reg. Health - West. Pac.* **14**, 100241 (2021).

10. Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-

income countries. *Nat. Med.* **27**, 1385–1394 (2021).

11. Schmid, P., Rauber, D., Betsch, C., Lidolt, G. & Denker, M.-L. Barriers of Influenza

Vaccination Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy,

2005 – 2016. *PLOS ONE* **12**, e0170550 (2017).

12. Rane, M. S. *et al.* Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine

Uptake in a National Cohort of US Adults: A Longitudinal Study. *Am. J. Epidemiol.* **191**,

570–583 (2022).

13. Caserotti, M. *et al.* Associations of COVID-19 risk perception with vaccine hesitancy over

time for Italian residents. *Soc. Sci. Med.* **272**, 113688 (2021).

14. Ghaznavi, C. *et al.* Factors associated with reversals of COVID-19 vaccination willingness:

Results from two longitudinal, national surveys in Japan 2021-2022. *Lancet Reg. Health -*

West. Pac. **27**, 100540 (2022).

15. Peterson, P., McNabb, P., Maddali, S. R., Heath, J. & Santibañez, S. Engaging Communities

to Reach Immigrant and Minority Populations: The Minnesota Immunization Networking

Initiative (MINI), 2006-2017. *Public Health Rep.* **134**, 241–248 (2019).

16. Sato, R. & Fintan, B. Effect of cash incentives on tetanus toxoid vaccination among rural

Nigerian women: a randomized controlled trial. *Hum. Vaccines Immunother.* **16**, 1181–1188

(2020).

17. Freeman, D. *et al.* COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus

explanations, attitudes, and narratives survey (Oceans) II. *Psychol. Med.* **52**, 3127–3141

(2022).

18. Fridman, A., Gershon, R. & Gneezy, A. COVID-19 and vaccine hesitancy: A longitudinal

study. *PLOS ONE* **16**, e0250123 (2021).

19. Loomba, S., De Figueiredo, A., Piatek, S. J., De Graaf, K. & Larson, H. J. Measuring the

impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. *Nat.*

Hum. Behav. **5**, 337–348 (2021).

20. Duncan, L. *et al.* Factors Affecting Parental Intent to Vaccinate Against COVID-19 in the

United States. *Kans. J. Med.* **17**, 51–56 (2024).

21. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur.*

J. Epidemiol. **35**, 775–779 (2020).

22. Schwarzinger, M., Watson, V., Arwidson, P., Alla, F. & Luchini, S. COVID-19 vaccine

hesitancy in a representative working-age population in France: a survey experiment based

on vaccine characteristics. *Lancet Public Health* **6**, e210–e221 (2021).

23. Pertwee, E., Simas, C. & Larson, H. J. An epidemic of uncertainty: rumors, conspiracy

theories and vaccine hesitancy. *Nat. Med.* **28**, 456–459 (2022).

24. Mutombo, P. N. *et al.* COVID-19 vaccine hesitancy in Africa: a call to action. *Lancet Glob.*

Health **10**, e320–e321 (2022).

25. Hou, Z. *et al.* Assessing COVID-19 Vaccine Hesitancy, Confidence, and Public Engagement:

A Global Social Listening Study. *J. Med. Internet Res.* **23**, e27632 (2021).

26. Zhang, Q., Zhang, R., Wu, W., Liu, Y. & Zhou, Y. Impact of social media news on COVID-

19 vaccine hesitancy and vaccination behavior. *Telemat. Inform.* **80**, 101983 (2023).

27. Siegrist, M. & Zingg, A. The Role of Public Trust During Pandemics: Implications for Crisis

Communication. *Eur. Psychol.* **19**, 23–32 (2014).

28. Rief, W. Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of

the Treatment Expectation Expert Group. *JAMA Health Forum* **2**, e210804 (2021).

29. Hornsey, M. J., Finlayson, M., Chatwood, G. & Begeny, C. T. Donald Trump and

vaccination: The effect of political identity, conspiracist ideation and presidential tweets on

vaccine hesitancy. *J. Exp. Soc. Psychol.* **88**, 103947 (2020).

30. De Munter, A. C. *et al.* Determinants of HPV-vaccination uptake and subgroups with a lower

uptake in the Netherlands. *BMC Public Health* **21**, 1848 (2021).

31. Kannan, V. D. & Veazie, P. J. Political orientation, political environment, and health

behaviors in the United States. *Prev. Med.* **114**, 95–101 (2018).

32. Stoeckel, F., Carter, C., Lyons, B. A. & Reifler, J. The politics of vaccine hesitancy in

Europe. *Eur. J. Public Health* **32**, 636–642 (2022).

33. Jones, D. R. & McDermott, M. L. Partisanship and the Politics of COVID Vaccine

Hesitancy. *Polity* **54**, 408–434 (2022).

34. Bilewicz, M. & Soral, W. The Politics of Vaccine Hesitancy: An Ideological Dual-Process

Approach. *Soc. Psychol. Personal. Sci.* **13**, 1080–1089 (2022).

35. Hotez, P. J. America's deadly flirtation with antiscience and the medical freedom movement.

J. Clin. Invest. **131**, e149072 (2021).

36. Kuznetsova, L., Diago-Navarro, E., Mathu, R. & Trilla, A. Effectiveness of COVID-19

Vaccination Mandates and Incentives in Europe. *Vaccines* **10**, 1714 (2022).

37. Duch, R. *et al.* Financial incentives for COVID-19 vaccines in a rural low-resource setting: a

cluster-randomized trial. *Nat. Med.* **29**, 3193–3202 (2023).

38. Comerford, D. *et al.* Did Negative News Regarding the Oxford AstraZeneca Vaccine end in

Vaccine Hesitancy? A Repeated Cross-Section Event Study from the UK. Preprint at

https://doi.org/10.21203/rs.3.rs-355311/v1 (2021).

39. De Albuquerque Veloso Machado, M., Roberts, B., Wong, B. L. H., Van Kessel, R. &

Mossialos, E. The Relationship Between the COVID-19 Pandemic and Vaccine Hesitancy: A

Scoping Review of Literature Until August 2021. *Front. Public Health* **9**, 747787 (2021).

40. Sønderskov, K. M., Dinesen, P. T. & Østergaard, S. D. Sustained COVID-19 vaccine

willingness after safety concerns over the Oxford-AstraZeneca vaccine.

41. Thirumurthy, H., Milkman, K. L., Volpp, K. G., Buttenheim, A. M. & Pope, D. G.

Association between statewide financial incentive programs and COVID-19 vaccination

rates. *PLOS ONE* **17**, e0263425 (2022).

42. Jacobson, M., Chang, T. Y., Shah, M., Pramanik, R. & Shah, S. B. Can financial incentives

and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A

randomized trial. *Vaccine* **40**, 6235–6242 (2022).

43. Wang, Z., Fang, Y., Yu, F., Chan, P. S. & Chen, S. Governmental Incentives, Satisfaction

with Health Promotional Materials, and COVID-19 Vaccination Uptake among Community-

Dwelling Older Adults in Hong Kong: A Random Telephone Survey. *Vaccines* **10**, 732

(2022).

44. The Government of the Hong Kong Special Administrative Region. Suspension of BioNTech

vaccination. https://www.info.gov.hk/gia/general/202103/24/P2021032400357.htm (2021).

45. Kwan, R. How Hong Kong's vaccination missteps led to the world's highest covid-19 death

rate. *BMJ* o1127 (2022) doi:10.1136/bmj.o1127.

46. The Government of the Hong Kong Special Administrative Region. Expert Committee on

Clinical Events Assessment Following COVID-19 Immunisation assesses serious adverse

events relating to COVID-19 vaccination.

https://www.info.gov.hk/gia/general/202106/01/P2021060100985.htm?fontSize=1 (2021).

47. The Government of the Hong Kong Special Administrative Region. Vaccine incentives in

place. https://www.news.gov.hk/eng/2021/06/20210609/20210609_153435_666.html.

48. Du, Z. *et al.* Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong. *Proc. Natl.*

Acad. Sci. **119**, e2213313119 (2022).

49. Yuan, J. *et al.* Dynamic predictors of COVID-19 vaccination uptake and their

interconnections over two years in Hong Kong. *Nat. Commun.* **15**, 290 (2024).

50. Siu, J. Y., Cao, Y. & Shum, D. H. K. Perceptions of and hesitancy toward COVID-19

vaccination in older Chinese adults in Hong Kong: a qualitative study. *BMC Geriatr.* **22**, 288

(2022).

51. Xiao, J. *et al.* Temporal changes in factors associated with COVID-19 vaccine hesitancy and

uptake among adults in Hong Kong: Serial cross-sectional surveys. *Lancet Reg. Health -*

West. Pac. **23**, 100441 (2022).

52. Leung, C. L. K. *et al.* Temporal variations of vaccine hesitancy amid the COVID-19

outbreaks in Hong Kong. *Appl. Psychol. Health Well-Being* **16**, 216–234 (2024).

53. The Government of the Hong Kong Special Administrative Region. Government explains

isolation and quarantine arrangement for COVID-19 cases and close contacts involving sub-

lineages of Omicron mutant strain.

https://www.info.gov.hk/gia/general/202206/01/P2022060100846.htm (2022).

54. Yu, B., Li, Q., Chen, J. & He, D. The impact of COVID-19 vaccination campaign in Hong

Kong SAR China and Singapore. *Infect. Dis. Model.* **8**, 101–106 (2023).

55. Miyachi, T., Takita, M., Senoo, Y. & Yamamoto, K. Lower trust in national government links

to no history of vaccination. *The Lancet* **395**, 31–32 (2020).

56. Thorpe, A. *et al.* Communicating about COVID-19 vaccine development and safety. *PLOS*

ONE **17**, e0272426 (2022).

57. Bak-Coleman, J. B. *et al.* Combining interventions to reduce the spread of viral

misinformation. *Nat. Hum. Behav.* (2022) doi:10.1038/s41562-022-01388-6.

58. Yao, Y., Zhou, H., Cao, Z., Zeng, D. D. & Zhang, Q. Optimal adaptive nonpharmaceutical

interventions to mitigate the outbreak of respiratory infections following the COVID-19

pandemic: a deep reinforcement learning study in Hong Kong, China. *J. Am. Med. Inform.*

Assoc. **30**, 1543–1551 (2023).

59. Cheng, W. *et al.* Future trajectory of respiratory infections following the COVID-19

pandemic in Hong Kong. *Chaos Interdiscip. J. Nonlinear Sci.* **33**, 013124 (2023).

60. Hong Kong. Open Data Portal. https://data.gov.hk/en/.

61. Prem, K. *et al.* Projecting contact matrices in 177 geographical regions: An update and

comparison with empirical data for the COVID-19 era. *PLOS Comput. Biol.* **17**, e1009098

(2021).

62. COVID-19 Community Mobility Reports. https://www.google.com/covid19/mobility/.

63. Apple Maps Mobility Trends Reports. https://covid19.apple.com/mobility.

64. MCMC toolbox for Matlab. https://mjlaine.github.io/mcmcstat/.

65. Li, Y. *et al.* The temporal association of introducing and lifting non-pharmaceutical

interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling

study across 131 countries. *Lancet Infect. Dis.* **21**, 193–202 (2021).

66. Department of Health. Press Release. https://www.dh.gov.hk/english/press/press.html.

67. Oriental Daily News. Former Oriental Daily. https://orientaldaily.on.cc/section/archive.

Acknowledgements

495   This work was supported in part by the Research Grants Council of the Hong Kong Special

496   Administrative Region, China (Ref. No. 11218221, C7154-20GF, C7151-20GF and C1143-

497   20GF to Q.Z.), and in part by the Health and Medical Research Fund (Ref. No: COVID190215

498   to H.-Y.Y. and Q.Z.). The funders had no role in study design, data collection and analysis,

499   decision to publish or preparation of the manuscript.

Author contributions

501   Q.Z. and Y.Y. designed and oversaw the study. Y.C. contributed to data collection, data analysis

502   and data interpretation under the supervision of Q.Z. Y.C wrote the manuscript. Y.Y contributed

503   to revising the manuscript. Q.Z. and H.Y.Y contributed to the interpretation of the findings and

504   revising the manuscript. All authors approved the submitted version and have contributed to the

505   final version of this manuscript.

Competing interests

507   The authors declare no competing interests.

Figure legends

Figure 1. COVID-19 epidemic dynamics and vaccination in Hong Kong (Jan. 2020-Oct. 2022).

(a) Daily new reported infected cases (blue circles) and model-fitted transmission trend (red line;

95% CI shaded); (b)-(c) Daily count of vaccination (magenta diamonds) and model-fitted

vaccination rates; (d) Zoomed-in view of the marked period in panel a (dashed shaded grey box)

showing detailed fitting. Black dotted line in panel b and c show timepoints of fitting

segmentation (E0-E2). Gray dashed lines in panel b show timepoints of four critical events (T1-

T4).

Figure 2. COVID-19 epidemic dynamics and vaccination over time under scenarios without

incentive measures (primary vaccination series phase). (a) The transmission trend; (b)

Vaccination rates. The solid curves and bands represent the mean of fitted or simulated results,

and 95% confidence intervals, respectively. The simulated results of scenarios are represented in

yellow, teal, purple and dark brown, respectively.

Figure 3. COVID-19 epidemic dynamics and vaccination over time (primary vaccination series

phase). (a)-(b) The transmission trend and vaccination rates under four scenarios. The solid

curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals,

respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark

brown, respectively.

Figure 5. COVID-19 epidemic dynamics over time (booster vaccination phase). The

transmission trend under three scenarios. The solid curves and bands represent the mean of fitted

or simulated results, and 95% confidence intervals, respectively. The simulated results of

scenarios are represented in teal, dark brown and light blue, respectively.

Tables

Table 1. The impact of different events on vaccine uptake.

Timepoints of events	Events	Potential 5C scale	Payoff gains for primary vaccination series
2021.03.24	E0: Vaccine packaging defects	Confidence	-130.8(-232.4%)
2021.04.19	T1: Serious adverse events after vaccination	Confidence	-71.9(-100.7%)
2021.05.26	T2: Government and business incentive measures	Constraints, confidence	64.6(90.6%)
2021.06.01	T3: Reduced information about deaths possibly linked to vaccination	Confidence, calculation	-55.0(-77.1%)
2021.08.08	T4: End of the incentive measures	Constraints	-67.5(-94.6%)

532   **Figures**

533   **Fig. 1.**

535 **Fig. 2.**

Fig. 3.

Fig. 4.